SRPT Sarepta Therapeutics, Inc. Stock Quote

SRPT [NASD]

Index	-	P/E	-	EPS (ttm)	-5.87	Insider Own	3.80%	Shs Outstand	87.51M	Perf Week	3.28%
Market Cap	9.95B	Forward P/E	-	EPS next Y	-4.12	Insider Trans	1.40%	Shs Float	83.78M	Perf Month	1.28%
Income	-506.60M	PEG	-	EPS next Q	-1.43	Inst Own	83.60%	Short Float	8.18%	Perf Quarter	57.33%
Sales	835.20M	P/S	11.91	EPS this Y	27.50%	Inst Trans	0.19%	Short Ratio	7.05	Perf Half Y	35.73%
Book/sh	8.30	P/B	13.60	EPS next Y	23.50%	ROA	-17.10%	Target Price	128.21	Perf Year	43.69%
Cash/sh	21.88	P/C	5.16	EPS next 5Y	-	ROE	-68.00%	52W Range	61.28 - 116.91	Perf YTD	25.37%
Dividend	-	P/FCF	-	EPS past 5Y	1.30%	ROI	-17.90%	52W High	0.91%	Beta	1.19
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	164.50%	Gross Margin	85.10%	52W Low	92.52%	ATR	4.07
Employees	840	Current Ratio	4.50	Sales Q/Q	42.30%	Oper. Margin	-53.00%	RSI (14)	72.70	Volatility	3.48% 3.42%
Optionable	Yes	Debt/Eq	1.52	EPS Q/Q	-159.10%	Profit Margin	-60.70%	Rel Volume	1.65	Prev Close	112.90
Shortable	Yes	LT Debt/Eq	1.52	Earnings	Aug 02 AMC	Payout	-	Avg Volume	972.92K	Price	117.97
Recom	1.90	SMA20	7.20%	SMA50	23.28%	SMA200	44.38%	Volume	319,593	Change	4.50%

Apr-04-22

Resumed

Cantor Fitzgerald

Overweight

$140

Jan-05-22

Reiterated

Needham

Buy

$157 → $150

Dec-09-21

Upgrade

Oppenheimer

Perform → Outperform

$125

Nov-05-21

Upgrade

JP Morgan

Neutral → Overweight

$130

Sep-15-21

Upgrade

Guggenheim

Neutral → Buy

Aug-05-21

Upgrade

JP Morgan

Underweight → Neutral

$92 → $87

Jun-15-21

Initiated

BTIG Research

Buy

$110

Apr-26-21

Resumed

Credit Suisse

Neutral

$72

Jan-12-21

Downgrade

Citigroup

Buy → Neutral

$215 → $108

Jan-11-21

Downgrade

UBS

Buy → Neutral

Jan-08-21

Downgrade

Raymond James

Outperform → Mkt Perform

Jan-08-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$95

Jan-08-21

Downgrade

JP Morgan

Overweight → Underweight

$96

Nov-11-20

Initiated

Berenberg

Hold

Oct-28-20

Initiated

UBS

Buy

$212

Aug-25-20

Initiated

Raymond James

Outperform

$200

Aug-20-20

Downgrade

Credit Suisse

Outperform → Neutral

$185 → $167

Mar-31-20

Initiated

Mizuho

Buy

$183

Nov-01-19

Initiated

Guggenheim

Buy

$183

Aug-21-19

Reiterated

Needham

Buy

$196 → $170

Sep-07-22 10:08AM	Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA Zacks
08:30AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year GlobeNewswire
Sep-06-22 09:27AM	FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial Benzinga
08:45AM	Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference GlobeNewswire
08:30AM	Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Sep-02-22 11:31AM	Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue? Zacks
Sep-01-22 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report? Zacks
Aug-31-22 05:59PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-22 01:47PM	15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome Investor's Business Daily
Aug-29-22 10:23AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
Aug-25-22 06:08AM	Trade Alert: Michael Chambers At Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Has Just Spent US$5.0m Buying 61% More Shares Simply Wall St.
Aug-17-22 06:43PM	Did Sarepta Therapeutics Just Unveil a Breakthrough? TheStreet.com
Aug-15-22 10:44AM	Billionaire Ray Dalio Loads Up on These 3 Strong Buy Stocks TipRanks
Aug-12-22 03:45PM	These Four Biotech Stocks Sparkle In IBD 50 Investor's Business Daily
Aug-08-22 02:09PM	Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications Benzinga +5.14%
08:30AM	Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases GlobeNewswire
Aug-03-22 02:20PM	Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts Benzinga
12:44PM	Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust Zacks
Aug-02-22 11:30PM	Sarepta Therapeutics (SRPT) Q2 2022 Earnings Call Transcript Motley Fool
05:25PM	Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments GlobeNewswire
09:11AM	Top 10 Stock Picks of Eli Casdins Casdin Capital Insider Monkey
Aug-01-22 01:59PM	Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More Zacks
08:41AM	Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength? Zacks
07:44AM	When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Breakeven? Simply Wall St.
Jul-29-22 06:25PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +8.17%
01:53PM	Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst Benzinga
01:22PM	Why Sarepta Therapeutics Stock Is Perking Up Today Motley Fool
10:40AM	Sarepta Will Seek Approval of Gene Therapy Before Completing Phase 3 Trial Barrons.com
07:00AM	Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy GlobeNewswire
Jul-28-22 10:03AM	Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-22 08:30AM	Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022 GlobeNewswire
Jul-18-22 04:13PM	IBD 50 Stocks To Buy And Watch: Gene Therapy Leader Gains On New Data, Potential FDA Approval Investor's Business Daily
Jul-12-22 12:00PM	Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy Zacks
Jul-06-22 09:55AM	Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial Benzinga
08:15AM	Sarepta Therapeutics Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies GlobeNewswire
03:00AM	Sarepta Wants to Speed Up Approval of Its Gene Therapy. What It Means for the Stock. Barrons.com
Jul-05-22 04:01PM	Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET GlobeNewswire
Jul-04-22 08:41AM	The Sarepta Therapeutics Pipeline No One is Talking About TheStreet.com
Jun-30-22 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:30AM	The Petri Dish: Sarepta hit with clinical hold, Decibel stock soars American City Business Journals
Jun-27-22 08:41AM	What Type Of Shareholders Own The Most Number of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares? Simply Wall St.
Jun-24-22 09:45AM	Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051 Zacks
Jun-23-22 04:11PM	Sarepta stock plunges after FDA puts study on hold MarketWatch +5.14%
04:01PM	Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
07:30AM	invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs GlobeNewswire
Jun-03-22 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report? Zacks
Jun-02-22 04:05PM	Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors GlobeNewswire
08:30AM	Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference GlobeNewswire
May-31-22 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-27-22 01:24PM	Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt? Simply Wall St. +5.29%
May-20-22 02:28PM	Ohio gene therapy industry gets 'buzz' but needs to sell itself more American City Business Journals
May-10-22 10:56AM	Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1 Zacks
May-09-22 11:49AM	Bullish insiders bet US$2.3m on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St. -7.13%
May-05-22 09:31AM	Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust Zacks
05:30AM	Sarepta Therapeutics (SRPT) Q1 2022 Earnings Call Transcript Motley Fool
May-04-22 05:25PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments GlobeNewswire
08:30AM	Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference GlobeNewswire
Apr-29-22 06:23PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-27-22 03:03PM	Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
08:30AM	Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022 GlobeNewswire
Apr-07-22 04:04PM	Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating Investor's Business Daily
Mar-31-22 06:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
11:30AM	Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report? Zacks
Mar-30-22 02:49PM	Despite currently being unprofitable, Sarepta Therapeutics (NASDAQ:SRPT) has delivered a 173% return to shareholders over 5 years Simply Wall St.
Mar-16-22 01:30PM	For pharma companies, revenue isn't so straightforward American City Business Journals
Mar-08-22 08:30AM	Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program GlobeNewswire
Mar-02-22 04:30PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
10:16AM	Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust Zacks
Mar-01-22 05:55PM	Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments GlobeNewswire
Feb-28-22 06:17PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:55AM	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-22-22 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022 GlobeNewswire
06:16AM	When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St.
Feb-03-22 05:38PM	Summit Wealth & Retirement Planning, Inc. ... GuruFocus.com
Feb-01-22 08:00AM	Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases GlobeNewswire
Jan-31-22 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-19-22 05:38PM	Financial Management Network Inc Buys BTC iShares MSCI EAFE Min Vol Factor ETF, Healthcare ... GuruFocus.com
Jan-17-22 11:27AM	What Type Of Shareholders Own The Most Number of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares? Simply Wall St.
Jan-12-22 09:38AM	DnB Asset Management AS Buys Check Point Software Technologies, Apple Inc, Accenture PLC, Sells ... GuruFocus.com
Jan-11-22 10:22AM	Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress Zacks
Jan-10-22 10:50AM	Sarepta Therapeutics Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire -10.94%
Jan-06-22 08:32AM	Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-21 08:45PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:30AM	Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why Zacks
Dec-28-21 09:50AM	Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day Zacks
Dec-27-21 10:15AM	3 Biotech Stocks Worth Adding to Your Portfolio Next Year Zacks
Dec-25-21 11:38AM	Sit Mid Cap Growth Fund Buys Darling Ingredients Inc, CommScope Holding Co Inc, Encompass ... GuruFocus.com
Dec-23-21 11:57AM	'Unmovable monster': The drug trial that changed how biotechs approach rare disease treatments American City Business Journals
Dec-22-21 11:35AM	The Zacks Analyst Blog Highlights: Daqo New Energy, Pinterest, Sarepta Therapeutics, JOYY and Chindata Group Zacks
10:27AM	Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal Zacks
Dec-21-21 11:24AM	Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline Zacks
06:53AM	These 5 Loser Stocks of 2021 Could be Big Winners in 2022 Zacks
Dec-20-21 11:07AM	Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids Zacks
Dec-17-21 01:38PM	Hedge Funds Are Souring On Sarepta Therapeutics Inc (SRPT) Insider Monkey
10:35AM	Emergent (EBS) Begins Dosing in Study on Influenza Vaccine Zacks
10:06AM	uniQure (QURE) Falls on Data From Huntington's Disease Study Zacks
Dec-16-21 10:00AM	Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication Zacks

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chambers Michael Andrew	Director	Aug 19	Buy	108.28	46,170	4,999,230	51,078	Aug 22 08:30 AM
BEHRENS M KATHLEEN	Director	Dec 15	Option Exercise	10.08	5,000	50,400	135,517	Dec 16 08:00 PM
GRAY MARY ANN	Director	Dec 10	Option Exercise	0.00	967	0	9,403	Dec 14 08:02 PM
Rodino-Klapac Louise	Head of R&D, CSO	Nov 24	Buy	79.33	3,780	299,867	65,678	Nov 29 08:00 AM
INGRAM DOUGLAS S	President & CEO	Nov 17	Buy	79.94	25,026	2,000,578	365,082	Nov 17 06:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience